share_log

NovaBay Pharmaceuticals To Reconvene Special Meeting Of Stockholders To December 18, 2024; Initial Meeting Adjourned Due To Insufficient Votes To Reach The 50% Threshold Of Outstanding Common Shares Voting In Favor Of Proposal One And Two

NovaBay Pharmaceuticals To Reconvene Special Meeting Of Stockholders To December 18, 2024; Initial Meeting Adjourned Due To Insufficient Votes To Reach The 50% Threshold Of Outstanding Common Shares Voting In Favor Of Proposal One And Two

novabay pharmaceuticals将于2024年12月18日重新召开股东特别大会;由于未能获得超过50%的持续普通股中提案一和二赞成投票,初始会议已经中止。
Benzinga ·  2024/11/23 05:08

Initial meeting adjourned due to insufficient votes to reach the 50% threshold of outstanding common shares voting in favor of Proposal One and Proposal Two

初次会议因未能获得足够票数通过第一和第二提案的50%阈值而延期

Stockholders who have not voted are strongly encouraged to vote FOR Proposal One and Proposal Two

强烈鼓励未投票的股东投票支持提案一和提案二

NovaBay Pharmaceuticals, Inc. (NYSE:NBY) ("NovaBay" or the "Company") announces that its Special Meeting of Stockholders held on November 22, 2024 has been adjourned until December 18, 2024 at 11:00 a.m. Pacific time to provide stockholders additional time to vote on Proposal One and Proposal Two. Both proposals received significant support based on the shares that have been voted by stockholders but have yet to reach the 50% threshold of favorable votes of all outstanding shares of common stock required to approve each proposal.

novabay pharmaceuticals公司(纽交所股票代码:NBY)(“novabay”或“公司”)宣布,其股东特别大会已于2024年11月22日召开,并将会议延期至2024年12月18日上午11:00太平洋时间,以为股东提供额外时间投票支持提案一和提案二。两项提案得到了大量股东已投票股份的支持,但尚未达到批准每项提案所需的所有未对投票的普通股的50%赞成票阈值。

  • Proposal One is a proposal to approve the sale of Avenova, representing substantially all of the assets of the Company (the "Asset Sale"), pursuant to the Asset Purchase Agreement, dated September 19, 2024, by and between the Company and PRN Physician Recommended Nutriceuticals, LLC.
    • Proposal Two is a proposal to approve the liquidation and dissolution of the Company, pursuant to the Plan of Complete Liquidation and Dissolution of the Company (the "Plan of Dissolution") which, if approved, would authorize the Company to liquidate and dissolve in accordance with the Plan of Dissolution, and pursuant to the discretion of the Board of Directors to proceed with the dissolution.
  • 提案一是批准出售Avenova资产(公司几乎所有资产)的提案(“资产出售”),根据由公司和PRN Physician Recommended Nutriceuticals, LLC于2024年9月19日订立的资产购买协议进行。
    • 提案二是批准公司清算和解散的提案,根据公司完全清算和解散计划(“解散计划”)进行,如果获得批准,将授权公司根据解散计划进行清算和解散,并由董事会自行决定是否继续进行解散。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发